Linkedin Instagram Youtube Facebook
Home
Summary of Audit Measures on Anaemia of CKD

Summary of Audit Measures on Anaemia of CKD

  1. Proportion of people starting an ESA without prior measurement of serum ferritin and TSAT (or % HRC or CHr or Ret-He).
  2. Proportion of people with non-dialysis dependent CKD with an eGFR < 30 ml/min/1.73m2 (CKD-EPI) with an annual haemoglobin level.
  3. Proportion of people with non-dialysis dependent CKD stage 4-5 with Hb 100-120 g/L.
  4. Proportion of people with dialysis dependent CKD on Peritoneal Dialysis receiving iron therapy; type: oral vs. parenteral.
  5. Proportion of people with non-dialysis dependent CKD and people receiving PD who are iron replete.
  6. Proportion of people on HD who are iron replete.
  7. Proportion of people with non-dialysis dependent CKD with serum ferritin >600 mcg/L.
  8. Proportion of people on HD with a serum ferritin >700 mcg/L or TSAT >40 %.
  9. Proportion of people with non-dialysis dependent CKD and heart failure and non-dialysis dependent CKD without anaemia who have iron parameters (ferritin and TSATs) checked in the last 4 months.
  10. Proportion of people with non-dialysis dependent CKD and heart failure with iron deficiency but preserved haemoglobin treated with iron.
  11. Proportion of people on kidney replacement therapy (haemodialysis or peritoneal dialysis for more than 3 months) with Hb < 100 g/L who are not prescribed an ESA.
  12. Proportion of people with non-dialysis dependent CKD with serum ferritin levels < 100 microgram/L, %HRC >6% or a Chr/Ret-He <31 pg at start of treatment with ESA or HIF-PHI.
  13. Proportion of people with dialysis-dependent CKD with serum ferritin levels < 200 micrograms/L, %HRC >6% or a Chr/Ret-He <31 pg at start of treatment with ESA or HIF-PHI.
  14. The proportion of people with CKD treated with an ESA or HIF-PHI with Hb > 120 g/L.
  15. Mean (median) ESA dose in people with CKD maintained on ESA therapy.
  16. Mean (median) HIF-PHI dose in people with CKD maintained on HIF-PHI therapy.
  17. Prevalence of resistance or hyporesponsiveness to ESA among people receiving kidney replacement therapy.
  18. The proportion of people with anaemia associated with CKD treated with HIF-PHI requiring IV iron infusions.
  19. Proportion of people receiving HD who received a blood transfusion within the previous year.
  20. Proportion of people with advanced non-dialysis dependent CKD (eGFR <30 ml/min/1.73m2) who received a blood transfusion in the previous year.